Day: December 24, 2024

Press Release Atos SE announces the appointment of FORVIS MAZARS as joint statutory auditor to certify the financial statements for the fiscal year ending December 31, 2024 Paris, France – 24 December 2024 – Atos SE (Euronext Paris : ATO) (the “Company” or “Atos”) announces the appointment, by interim order (ordonnance de référé) of the President of the Pontoise Commercial Court on December 19, 2024, of FORVIS MAZARS, selected following a call for tenders, as the Company’s new joint statutory auditor, to certify the financial statements for the fiscal year ending December 31, 2024, alongside Grant Thornton. It is reminded that the mandate of Deloitte & Associés as statutory auditor, appointed on May 18, 2018 for a term of six fiscal years, could not be extended for regulatory reasons and will therefore expire at the end of the...

Regulated information, Leuven, 24 December 2024 (07.45 hrs CET) KBC Group shareholder syndicate following extension of shareholder agreements Cera and KBC Ancora, together with MRBB and the other stable shareholders, confirmed on 29 November 2024 they would be extending unchanged their anchoring agreement with respect to KBC Group for a further term of ten years. The extension of the syndicate agreement came into effect on 1 December 2024. Cera, KBC Ancora, MRBB and the Other Stable Shareholders will henceforth group together 41.75% of the total number of KBC Group shares. In this way, the shareholders concerned will continue to ensure the shareholder stability and development of the KBC group. Together with MRBB and the Other Stable Shareholders (AVAs), Cera and KBC Ancora are ensuring the shareholder stability and development of the...

KELLOGG, Idaho and VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSXV:BNKR | OTCQB:BHLL) announces certain updates to its news release dated December 20, 2024 in connection with the Company’s election to issue an aggregate of up to 8,446,194 shares of common stock of the Company (“Common Shares”) in full satisfaction of debenture interest payment obligations and outstanding financing cooperation fees, including: (i) an aggregate of up to 7,392,859 Common Shares (the “Interest Shares”) to certain holders of 7.5% convertible debentures (the “Series 1 Convertible Debentures”) and 10.5% convertible debentures (the “Series 2 Convertible Debentures” and, together with the Series 1 Convertible Debentures, the “Convertible Debentures”) in full satisfaction of the...

VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and data center technology company, announces the issuance of US Patent No. 12,067,572 for Cryptographic Taint Tracking. This patent, issued by the US Patent and Trademark Office, is a continuation of the previously issued U.S. Patent No. 11,257,089. The original patent laid the foundation for a method to detect and track tainted cryptographic wallets, supporting efforts to combat money laundering and fraud. This new patent builds on the innovative technology behind Blockseer’s wallet risk scoring method, which reinforces DMG’s clean-block mining initiative and its use in mining pools. The patented methods enable...

• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 under Fast Track and Breakthrough Therapy Designations, Previously Granted to D-PLEX100 by the FDA; • Proceeds from this Financing and Exercise of Data-Triggered Warrant Expected to Extend Cash Runway Beyond Potential NDA Approval PETACH TIKVA, Israel, Dec. 24, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that following the independent Data Safety Monitoring Board’s (“DSMB”) review of unblinded efficacy data from the first 430 enrolled patients in the SHIELD II Phase 3 trial...